Pelthos Therapeutics (PTHS) Other Non-Current Liabilities (2025 - 2026)
Pelthos Therapeutics (PTHS) posted quarterly Other Non-Current Liabilities of $30.0 million for Q4 2025, up 14.8% quarter-over-quarter from $26.2 million in Q3 2025.
Pelthos Therapeutics (PTHS) Other Non-Current Liabilities (2025 - 2026) Analysis & Trends
Pelthos Therapeutics' Other Non-Current Liabilities history runs 1 years deep, the most recent figure standing at $30.0 million for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $30.0 million; the TTM figure through Dec 2025 stood at $30.0 million (changed N/A YoY), while the FY2025 annual figure was $30.0 million, changed N/A from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $30.0 million, up from $26.2 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $30.0 million in Q4 2025, with the low at $26.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pelthos Therapeutics | 91.09 Mn | 66.53 Mn | 21.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.41 Mn |
| Dec 31, 2025 | 30.05 Mn |
| Sep 30, 2025 | 26.18 Mn |